✦ LIBER ✦

Analysis of Court Criteria for Awarding Disability Benefits to Patients With Crohn's Disease

✍ Scribed by Calvet, Xavier; Motos, Jaime; Montserrat, Antònia; Gallardo, Olga; Vergara, Mercedes

Book ID: 123138964
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 234 KB
Volume: 7
Category: Article
ISSN: 1542-3565
DOI: 10.1016/j.cgh.2009.01.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

M1134 Criteria for Awarding Disability B

M1134 Criteria for Awarding Disability Benefits to Crohn's Disease Patients: A Study of Cases in Spanish Case Law

✍ Calvet, Xavier; Motos, Jaume; Montserrat, Antónia; Vergara, Mercedes 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Risk–benefit analysis of adalimumab vers

Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

✍ Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB 👁 1 views

Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis

Defining the Optimal Response Criteria f

Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease

✍ Thia, Kelvin T.; Sandborn, William J.; Lewis, James D.; Loftus, Jr, Edward V.; F 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 133 KB

T1197 A Risk-Benefit Analysis of Adalimu

T1197 A Risk-Benefit Analysis of Adalimumab vs. Standard of Care in Patients with Crohn's Disease

✍ Loftus, Edward V.; Colombel, Jean-Frédéric; Johnson, Scott J.; Wu, Eric; Chao, J 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 67 KB

644 Early Mucosal Healing Status Predict

644 Early Mucosal Healing Status Predicts Long-Term Clinical Benefits for Adalimumab-Treated Patients With Moderate to Severe Crohn's Disease

✍ Paul J. Rutgeerts; Walter Reinisch; Roopal Thakkar; Eric Q. Wu; Anna Kaltenboeck 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 52 KB

S1051 Methotrexate for the Prevention of

S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease

✍ Brian G. Feagan; John W. McDonald; Remo Panaccione; Robert A. Enns; Charles N. B 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 153 KB